Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 877757 | ISIN: FR0000051732 | Ticker-Symbol: AXI
Frankfurt
23.01.25
21:53 Uhr
0,002 Euro
0,000
0,00 %
1-Jahres-Chart
ATOS SE Chart 1 Jahr
5-Tage-Chart
ATOS SE 5-Tage-Chart
RealtimeGeldBriefZeit
0,0020,00222:32
0,0020,00220.12.24
GlobeNewswire (Europe)
606 Leser
Artikel bewerten:
(2)

Atos International: Atos Group and AWS launch Global GenAI Innovation Studio to accelerate AI-powered business transformation

Finanznachrichten News


Press Release

Atos Group and AWS launch Global GenAI Innovation Studio to accelerate AI-powered business transformation

Cutting-edge 6,000sqft facility unlocks the potential of generative AI, enabling organizations to accelerate innovation, transform customer experiences, and optimize productivity

Pune, India - October 15, 2024 - Atos Group,including Eviden, its business leading in digital, cloud, big data and security, today announces the launch of its global GenAI Innovation Studio in Pune, India, in partnership with AWS, the world's leading cloud provider.

The Studio will serve as a collaborative hub where Atos and AWS will co-develop groundbreaking GenAI solutions that tackle industry-specific challenges. Customers will have the opportunity to engage in envisioning sessions and hands-on proofs-of-value specifically tailored to their needs, accelerating their AI adoption and experiencing real-world generative AI applications.

The studio launch event welcomes customer delegations from around the globe, AWS experts, independent analysts, and Atos employees to an environment focused on shaping the future of AI. The Studio will host regular events fostering a culture of learning and innovation, including training and certification programs, hackathons, and AWS DeepRacer competitions.

Leveraging its industry knowledge, deep AWS expertise as a Premier Consulting Partner, and proficiency in digital, big data, and security, the Atos Group brings extensive capabilities to the Studio, enabling impactful solutions across sectors facing unprecedented challenges and opportunities.

Diane Galbe, Senior Executive Vice President, Atos Group: "We are thrilled to open this global co-innovation GenAI Studio with AWS. The center will foster close collaboration with our clients around the world, enabling us to develop solutions and accelerators that precisely address their specific needs and challenges. By harnessing the power of generative AI, we aim to empower our customers to fully leverage data and AI to drive transformation and innovation across all their activities."

Hervé Lemaire, Founder and President, Selartag: "Our collaboration with Eviden has enabled us to develop a cutting-edge application that empowers our customers to seamlessly locate, track, and document their wine inventory while minimizing errors and ensuring the authenticity of their bottles. This solution extends the exceptional service our customers provide to the entire value chain of their business. Eviden's comprehensive expertise in AWS services and project management has been crucial in delivering a truly differentiated solution, providing our customers with real-time data and operational efficiencies that gives a competitive edge."

Atos and AWS have been partners since 2013 and announced their pioneering CloudCatalyst agreementin 2022. The GenAI Innovation Studio is part of the 5-year Strategic Collaboration Agreement(SCA) established between Eviden and AWS at the end of last year.

Atos Group and AWS continue to collaborate on innovative cloud solutions aimed at accelerating growth and transformation for their customers.

To learn more about how Atos Group and AWS deliver customer business outcomes with GenAI and other innovative solutions, please visit https://eviden.com/about-us/partner-ecosystem/amazon-web-services-aws/.

***

About Atos

Atosis a global leader in digital transformation with c. 92,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea), and listed on Euronext Paris.

The purpose of Atosis to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Press contact
Laura Fau | laura.fau@eviden.com| +33 (0) 6 73 64 04 18

Attachment

  • PR - Atos Group and AWS launch Global GenAI Innovation Studio to accelerate AI-powered business transformation - final (https://ml-eu.globenewswire.com/Resource/Download/52f10821-8d44-4cc0-b559-b72a943fa042)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.